Article
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
3 Jan 2014
Abstract excerpt
INTRODUCTION: Intensive efforts, over the last decade, have been made to inhibit the kinase activity of cyclins that act as mediators during cell-cycle progression. Activation of the cyclin D1 oncogene, often by amplification or rearrangement, is a major driver of multiple types of human tumors including breast and squamous cell cancers, B-cell lymphoma, myeloma and parathyroid adenoma. AREAS COVERED: In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.